a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions
NCT ID: NCT01508520
Last Updated: 2012-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
146 participants
OBSERVATIONAL
2009-12-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. ME-NBI is useful in distinguishing EGC from other gastric lesions
2. ME-NBI is useful in further differential diagnosis among EGCs.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Predictive Model Based on Narrow Band Imaging for Early Gastric Cancerous Lesions
NCT02968069
Magnifying Endoscopy With Narrow Band Imaging Versus Endoscopic Ultrasonography for Prediction of Tumor Invasion Depth in Early Gastric Cancer: A Prospective Comparative Study
NCT03546257
Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFB
NCT02738294
Enhanced Magnifying Endoscopy for Diagnosis of Early Gastric Cancer
NCT01617876
Narrow Band Imaging (NBI) Against Lugol for Squamous Esophageal Cancer
NCT02002559
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients under unsuitable conditions for examination or treatment, such as acute upper gastrointestinal bleeding, noncorrectable coagulopathy, severe systemic disease, etc;
* inability to provide informed consent;
* inability to provide histology of resected specimens after endoscopic treatment or surgery.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiaobo Li
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaobo Li
Shanghai Institute of Digestive Disease,Renji Hospital, Shanghai Jiao Tong University School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaobo Li, MD. Ph.D
Role: PRINCIPAL_INVESTIGATOR
Shanghai Ren Ji Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
rjyyxhk6056
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.